Enterprise Value
-125.3M
Cash
491.8M
Avg Qtr Burn
-40.33M
Short % of Float
9.59%
Insider Ownership
11.84%
Institutional Own.
84.63%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zipalertinib (irreversible EGFR inhibitor) Details Non-small cell lung carcinoma | Phase 3 Update | |
Zipalertinib (irreversible EGFR inhibitor) Details Non-small cell lung carcinoma | Phase 2b Update | |
CLN-619 (MICA/B) Details Solid tumor/s | Phase 1 Data readout | |
CLN-418 (B7H4x4-1BB) Details Solid tumor/s | Phase 1 Data readout | |
CLN-049 (FLT3xCD3) Details Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia | Phase 1 Update | |
CLN-978 (CD19xCD3) Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1 Update | |
CLN-617 (IL-2 and IL-12) Details Cancer, Solid tumor/s | Phase 1 Initiation |